Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Leukemia
  •  Kidney Cancer
  •  Radiation Oncology
  •  Stomach Cancer
  •  General Oncology
  •  Adjuvant Therapy
  •  Chemotherapy and Radiotherapy
  •  Targeted Therapy


Citation: Clin Oncol. 2017;2(1):1309.DOI: 10.25107/2474-1663.1309

Association of Oral Contraceptives and Hormone Replacement Therapy with Pancreatic Cancer Risk in Women: A Meta-Analysis

Jin-Xiao Liang, Wei Gao, Xin-ming Zhou, Yong Liang and Jun Ling

Department of Thoracic Surgery, Zhejiang Cancer Hospital, Republic of China
Department of Biochemistry and Molecular Biology, Dalian Medical University, Republic of China
Department of Clinical Medicine, Taizhou University Medical School, Republic of China
Department of Basic Sciences, Geisinger Commonwealth School of Medicine, USA

*Correspondance to: Yong Liang 

 PDF  Full Text Research Article | Open Access


Although the incidence rate of pancreatic cancer is higher in men than in women, Oral Contraceptives (OC) and Hormone Replacement Therapy (HRT) commonly used in women may constitute a risk or protective factor for pancreatic cancer. Some studies have examined these relationships, but no coherent conclusions have been reached. Thus, we conducted a meta-analysis in this study by extensive search of literature using PubMed and EMBASE databases. It was found that OC use was associated with the significant decrease in pancreatic cancer risk (pooled OR 0.75, 95% CI 0.61-0.91). Subgroup analysis identified that OC decreased the risk in the pancreatic cancer population-based studies (pooled OR 0.76, 95 % CI 0.67-0.86) but was controversial in the hospital-based studies (pooled OR 1.21, 95% CI 0.94-1.57). HRT did not show the significant effect on pancreatic cancer risk (pooled OR 1.00, 95 % CI 0.79-1.26). However, subgroup analysis identified the decreased risk in North America population (pooled OR 0.81, 95% CI 0.65-1.01) but the increased risk in Europe population (pooled OR 1.51, 95% CI 1.16-1.97). In conclusion, OC use was demonstrated to have a protective effect against pancreatic cancer in women, where as HRT showed no effect or diverse effects in different populations. Our results increase the awareness of using HRT in women when considering pancreatic cancer risk. The subgroup analysis also suggests that more clinical studies are needed to clarify the specific relationship between OC or HRT and pancreatic cancer risk in different populations.


Pancreatic cancer; Oral contraceptives; Hormone replacement therapy; Risk factor, Meta-analysis

Cite the Article:

Liang J-X, Gao W, Zhou X-M, Liang Y, Ling J. Association of Oral Contraceptives and Hormone Replacement Therapy with Pancreatic Cancer Risk in Women: A Meta- Analysis. Clin Oncol. 2017; 2: 1309.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Research Progress on the Origin and Mechanism of Liver Cancer Stem Cells
 Abstract  PDF  Full Text
Transanal vs. Laparoscopic Transabdominal Intersphincteric Resection for Lower Rectal Cancer: Comparison of the Operative and Functional Outcomes
 Abstract  PDF  Full Text
View More...